What is the role of immunosuppressive therapy in active Takayasu's arteritis? 
A study conducted by Valsakumar et al in 2003 found that immunosuppressive therapy can have a positive effect on clinical, immunological and angiographic outcomes in active Takayasu's arteritis. Leflunomide, a DMARD, has also been found to be effective in treating Takayasu's arteritis in a long term observational study conducted by de Souza et al in 2016. Polymyalgia rheumatica and giant-cell arteritis were also studied in 2002 by Salvarani et al, finding that treatment of primary central nervous system vasculitis in children can be improved with an open-label cohort study. De Boysson et al in 2018, also found that treatment and long-term outcomes of primary central nervous system vasculitis can improve with effective treatment. 